Table 2.
Pharmacokinetic parameters for OR-1855 and OR-1896 after an intravenous infusion of levosimendan for 7 days (mean ± SD)
| OR-1855 | OR-1896 | |||||
|---|---|---|---|---|---|---|
| 0.05 µg kg−1 min−1 (n = 12) | 0.1 µg kg−1 min−1 (n = 12) | P value (95% CI) | 0.05 µg kg−1 min−1 (n = 12) | 0.1 µg kg−1 min−1 (n = 12) | P value (95% CI) | |
| Cmax (ng ml−1) | 7.8 ± 5.1 | 18.1 ± 11.2 | 0.009 (−17.8, −2.9) | 9.9 ± 4.7 | 17.1 ± 9.8 | 0.030 (−13.7, −0.76) |
| tmax (h)* | 168 (144–314) | 170 (144–216) | 0.301 (−23.4, 57.6) | 180 (144–264) | 170 (144–264) | 0.873 (−24.4, 28.6) |
| AUC(0,last) (ng ml−1 h) | 1570 ± 1220 | 3560 ± 2130 | 0.011 (−3477, −501) | 2120 ± 1260 | 3450 ± 2050 | 0.070 (−2770, 118.3) |
| AUC(0,∞) (ng ml−1 h) | 1650 ± 1260 | 3950 ± 2420 | 0.015 (−4085, −505) | 2370 ± 1820 | 3890 ± 2540 | 0.107 (−3388, 356.8) |
| t1/2 (h) | 72.6 ± 17.8 | 78.4 ± 27.8 | 0.579 (−27.4, 15.8) | 81.3 ± 37.1 | 81.2 ± 27.5 | 0.992 (−27.5, 27.7) |
*
median (range). Cmax peak concentration, tmax time to peak concentration, AUC(0,last) area under the curve to the last measured concentration, AUC(0,∞) area under the curve to infinity, t1/2 half-life, 95% CI 95% confidence intervals on the differences.